Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter clinical study of pediatric diffuse alveolar hemorrhage in China
ChiCTR1900026551Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Nov 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of hydroxychloroquine, azathioprine, methotrexate and cyclosporine in pulmonary alveolar hemorrhage (DAH) and Idiopathic Pulmonary Hemosiderosis (IPH) (6 arms), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoint: Remission rate. Planned start Nov 2019; status: not yet recruiting.
02
Drugs
hydroxychloroquineazathioprinemethotrexatecyclosporine
03
Conditions
pulmonary alveolar hemorrhage (DAH)Idiopathic Pulmonary Hemosiderosis (IPH)
Beyond the preview
Go deeper on ChiCTR1900026551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026551.